We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
- Authors
Schönfelder, Kristina; Schuh, Helene; Pfister, Frederick; Krämer, Julia; Eisenberger, Ute; Skuljec, Jelena; Hackert, Jana; Ruck, Tobias; Pfeuffer, Steffen; Fleischer, Michael; Gäckler, Anja; Hagenacker, Tim; Kribben, Andreas; Meuth, Sven G; Kleinschnitz, Christoph; Pul, Refik
- Abstract
Background: Oral cladribine is an approved disease-modifying drug for the treatment of relapsing multiple sclerosis. In controlled clinical trials as well as in post marketing safety assessments, autoimmune conditions have not yet been reported as a specific side effect of cladribine. Objective and Results: Here, we report a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis that occurred shortly after the fourth cladribine treatment cycle. Conclusion: Neurologists should be attentive to the development of secondary autoimmunity in cladribine-treated patients.
- Subjects
MULTIPLE sclerosis; CLINICAL trials; GLOMERULONEPHRITIS; SUBSTANCE abuse relapse; AUTOIMMUNE diseases
- Publication
Multiple Sclerosis Journal, 2021, Vol 27, Issue 12, p1960
- ISSN
1352-4585
- Publication type
Article
- DOI
10.1177/13524585211022719